
Promising Start for Race Oncology’s RC220 Trial Among ASX200 Developments
Highlights First patient safely dosed with RC220 and doxorubicin Trial expands across Australia, Hong Kong, and South Korea Early safety data supports future development milestones Race Oncology (ASX:RAC) has marked a significant clinical milestone with …